Supervivencia relativa a cinco años del cáncer de páncreas
El cáncer de páncreas es un diagnóstico difícil, porque el páncreas se encuentra en la profundidad de la cavidad abdominal, junto a vasos sanguíneos vitales. El pronóstico depende directamente de cuán temprano se detecte. Esta estadística muestra la proporción de pacientes que sobreviven cinco años después del diagnóstico, mientras que los porcentajes de distribución de casos muestran en qué etapa se suele encontrar el cáncer de páncreas. Por ejemplo, solo alrededor del 15 % de los cánceres de páncreas se detectan en la etapa 1 y, lamentablemente, cerca de la mitad se detectan en la etapa 4.
- Cáncer confinado al páncreas (etapa 1)
- Diseminación a tejidos o ganglios linfáticos cercanos (etapas 2–3)
- Metástasis en otros órganos, p. ej., el hígado (etapa 4)
La cifra global de supervivencia a cinco años del cáncer de páncreas está aumentando gradualmente y actualmente se sitúa en torno al 13.3 %,1 gracias a la mayor disponibilidad de tratamientos.
El cáncer de páncreas es una enfermedad dura — ¿cómo recuperarse?
Terapia enzimática: el cáncer de páncreas a menudo altera la producción natural de enzimas digestivas, por lo que tomar enzimas suplementarias con cada comida es esencial para mantener el peso. Dieta sin azúcar: debido a que las células cancerosas utilizan la glucosa como energía, una dieta con un mínimo de carbohidratos simples ayuda a crear un entorno desfavorable para el tumor. Control del peso: la pérdida de peso (caquexia) es uno de los mayores desafíos, por lo que la dieta debe ser rica en proteínas de fácil absorción.
Hongos medicinales y cáncer de páncreas
El tratamiento (especialmente la quimioterapia) debilita fuertemente el cuerpo. Los hongos medicinales se estudian como una forma de fortalecer la respuesta inmunitaria y mejorar la calidad de vida durante el tratamiento. El AHCC (de los hongos shiitake) es uno de los compuestos más estudiados, que ayuda a mantener la actividad de las células asesinas naturales (NK) y a reducir la toxicidad hepática y las náuseas inducidas por la quimioterapia. La cola de pavo (Coriolus versicolor) contiene PSK (polisacárido-K), que en algunos países se utiliza oficialmente junto con la quimioterapia, porque ayuda al sistema inmunitario a reconocer y combatir las células cancerosas.
Los polisacáridos de hongos AHCC y PSK se estudian junto con la quimioterapia para mantener la actividad de las células NK y reducir la toxicidad.
Lentinan AXT de Zenius Labs™ →Preguntas frecuentes
La supervivencia relativa global a cinco años es de aproximadamente un 13.3 % y está aumentando gradualmente gracias a mejores tratamientos. La supervivencia depende en gran medida de la etapa en el momento del diagnóstico — solo ~15 % se detectan en la etapa 1, mientras que aproximadamente la mitad se detectan en la etapa 4.
El páncreas se encuentra en la profundidad del abdomen, junto a vasos sanguíneos vitales, por lo que los síntomas aparecen tarde y el cáncer a menudo se detecta en una etapa avanzada. El pronóstico depende directamente de cuán temprano se detecte.
La terapia enzimática con las comidas ayuda a mantener el peso, una dieta baja en azúcar limita el suministro de energía del tumor y una nutrición rica en proteínas contrarresta la caquexia (pérdida de peso). Se estudian fórmulas concentradas de polisacáridos de hongos como Lentinan AXT de Zenius Labs™ para el apoyo inmunitario.
El AHCC (del shiitake) se estudia para mantener la actividad de las células NK y reducir la toxicidad y las náuseas de la quimioterapia, y el PSK (de la cola de pavo / Coriolus versicolor) se utiliza oficialmente junto con la quimioterapia en algunos países para ayudar al sistema inmunitario a combatir las células cancerosas.
- Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies. PubMed
- Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with immunostimulant in murine cancer model. PubMed
- Matrix stiffness and the Warburg effect in pancreatic cancer tumor growth. PubMed
- Capula M et al. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2022. PubMed
- Kim G nab-Paclitaxel for the treatment of pancreatic cancer. Cancer management and research. 2017. PubMed
- Zhang Y et al. Immune Therapy in Pancreatic Cancer: Now and the Future?. Reviews on recent clinical trials. 2015. PubMed
- Das S et al. Harnessing the Immune System in Pancreatic Cancer. Current treatment options in oncology. 2018. PubMed
- Carpenter ES et al. Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cancer research. 2020. PubMed
- Tang M et al. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?. Journal of controlled release : official journal of the Controlled Release Society. 2019. PubMed
- Zheng R et al. Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy. Oncology reports. 2026. PubMed
- Jiang S et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. Journal of experimental & clinical cancer research : CR. 2023. PubMed
- Goetze TO et al. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Annals of surgical oncology. 2024. PubMed
- Byrne JD et al. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer chemotherapy and pharmacology. 2018. PubMed
- Nywening TM et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. The Lancet. Oncology. 2016. PubMed
- Tran NH et al. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. International journal of radiation oncology, biology, physics. 2020. PubMed
- Lee JH et al. Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia. Cells. 2021. PubMed
- Zhang Y et al. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. International immunopharmacology. 2008. PubMed
- Yu X et al. Astaxanthin Ameliorates Skeletal Muscle Atrophy in Mice With Cancer Cachexia. Nutrition and cancer. 2024. PubMed
- Bossi P et al. The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients. 2021. PubMed
- Luo L et al. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. Nano today. 2024. PubMed
- Mortezaee K Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. Journal of biochemical and molecular toxicology. 2021. PubMed
- Liu X et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Science translational medicine. 2024. PubMed
- Datta J et al. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer. Gastroenterology. 2022. PubMed
- Lin HJ et al. Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma. Cancers. 2023. PubMed
- Chandrakesan P et al. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Molecular cancer therapeutics. 2020. PubMed
- Liu Y et al. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Cell death and differentiation. 2025. PubMed
- Zhou J et al. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance. Cancer letters. 2023. PubMed
- Deng Y et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nature communications. 2021. PubMed
- Zhou W et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021. PubMed
- Mukherji R et al. The Role of Immunotherapy in Pancreatic Cancer. Current oncology (Toronto, Ont.). 2022. PubMed
- Feng M et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer letters. 2017. PubMed
- Jolly G et al. Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic. Cancers. 2023. PubMed
- Bangolo AI et al. Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights. World journal of gastroenterology. 2023. PubMed
- Halle-Smith JM et al. Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies?. Cancers. 2023. PubMed
- Li P et al. Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives. Cancer letters. 2024. PubMed
- Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
- Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
- Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
- Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
- Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
- Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
- Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
- Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
- Sun M et al. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer. Surgical oncology. 2015. PubMed
- Zhang P et al. A carbon nanotube-gemcitabine-lentinan three-component composite for chemo-photothermal synergistic therapy of cancer. International journal of nanomedicine. 2018. PubMed
- Shimizu K et al. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepato-gastroenterology. 2009. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
- Geller AE et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nature communications. 2022. PubMed
- Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
- Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
- Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
- Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed